The SCQM program was founded in 1997 in Zürich as a quality management instrument of the treatment of rheumatoid arthritis. The input of data on disease activity, function, damage, quality of life etc. allows a targeted therapy and makes communication between patient and physician easier. The anonymised data is also used for research.
Published studies (selection)
Evolution of radiographic joint damage in rituximab-treated versus TNF-treated rheumatoid arthritis cases with inadequate response to TNF antagonists. Finckh A, Möller B, Dudler J, Walker UA, Kyburz D, Gabay C; physicians of the Swiss Clinical Quality Management for Rheumatoid Arthritis; physicians of SCQM-RA. Ann Rheum Dis. 71(10):1680-5, 2012
The long-term impact of early treatment of rheumatoid arthritis on radiographic progression: a population-based cohort study. Kyburz D, Gabay C, Michel BA, Finckh A; physicians of SCQM-RA. Rheumatology (Oxford). 50:1106-10, 2011.
Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Finckh A, Ciurea A, Brulhart L, Möller B, Walker UA, Courvoisier D, Kyburz D, Dudler J, Gabay C; Arthritis. Ann Rheum Dis. 69:387-93, 2010.